AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-34. (canceled)

35. (New) A method for enhancing an immune response of a host, which comprises administering to the host an antigen or a product of interest capable of inducing an immune response by the host, and a composition comprising a biologically acceptable carrier and a molecule selected from (i) GlcNAc-MurNAc-L-Ala-D-Glu-mesoDAP (MTP); (ii) MurNAc-L-Ala-D-Glu-mesoDAP; (iii) L-Ala-D-Glu-mesoDAP; and (iv) the molecule in which the L-Ala of (i), (ii), or (iii) is replaced with D-Ala, wherein the molecule is administered to the host in an amount sufficient to enhance the immune response.

36. (New) The method of claim 35, wherein the molecule is L-Ala-D-Glu-mesoDap or D-Ala-D-Glu-mesoDap.

37. (New) The method of claim 35, wherein the molecule is GlcNAc-MurNAc-L-Ala-D-Glu-mesoDAP (MTP) or GlcNAc-MurNAc-D-Ala-D-Glu-mesoDAP.

38 (New) The method of claim 35, wherein the molecule is MurNAc-L-Ala-D-Glu-mesoDAP or MurNAc-D-Ala-D-Glu-mesoDAP.

39. (New) A method for inducing an immune response in a host, which comprises administering to the host a composition comprising an antigen and an adjuvant, wherein the adjuvant comprises a tripeptide having the structure L-Ala-D-Glu-mesoDAP or D-Ala-D-Glu-mesoDap and wherein the amino acid Ala of said tripeptide is not linked to a N-acylmuramic acid.

40. (New) The method of claim 38, wherein the adjuvant comprises a tripeptide having the structure L-Ala-D-Glu-mesoDAP.

41. (New) The method of claim 38, wherein the adjuvant comprises a tripeptide having the structure of D-Ala-D-Glu-mesoDap.

42. (New) The method of claim 38, wherein the host is a human.

43. (New) The method of claim 38, wherein the host is a mammal or a bird.

44. (New) A method of vaccination in a human or animal host comprising administering to the host a composition comprising an antigen and an adjuvant, wherein the adjuvant comprises a tripeptide having the structure L-Ala-D-Glu-mesoDAP or D-Ala-D-Glu-mesoDap and wherein the amino acid Ala of said tripeptide is not linked to a N-acylmuramic acid.

45. (New) The method of claim 44, wherein the adjuvant comprises a tripeptide having the structure L-Ala-D-Glu-mesoDAP.

46. (New) The method of claim 38, wherein the adjuvant comprises a tripeptide having the structure of D-Ala-D-Glu-mesoDap.

47. (New) The method of claim 44, wherein the host is a human.

48. (New) The method of claim 44, wherein the host is a non-human animal.

49. (New) The method of claim 44, wherein the vaccination is against a bacterial pathogen.